Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

por Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., Flaig, T. W., Page, R. D., Beck, J. T., Cheung, F., Yadav, S., Patel, P., Geoffrois, L., Niolat, J., Berkowitz, N., Marker, M., Chen, D., Motzer, R. J.
Publicado 2017

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC

por Knox, J J, Barrios, C H, Kim, T M, Cosgriff, T, Srimuninnimit, V, Pittman, K, Sabbatini, R, Rha, S Y, Flaig, T W, Page, R D, Beck, J T, Cheung, F, Yadav, S, Patel, P, Geoffrois, L, Niolat, J, Berkowitz, N, Marker, M, Chen, D, Motzer, R J
Publicado 2018